Novel effect of ezetimibe to inhibit the development of non‐alcoholic fatty liver disease in Fatty Liver Shionogi mouse. Issue 1 (19th March 2013)

• Record Type: Journal Article
• Authors: Wang, Xiang; Sugimoto, Ken; Fujisawa, Tomomi; Shindo, Nobuyasu; Minato, Satomi; Kamada, Yoshihiro; Hamano, Mina; Ohishi, Mitsuru; Ikegami, Hiroshi; Rakugi, Hiromi
• Is Part Of: Hepatology research. Volume 44:Issue 1(2014:Jan.)
• Page Start: 102
• Page End: 113
• Publication Date: 2013-03-19
• Subjects: Liver -- Diseases -- Periodicals; Liver Diseases -- Periodicals; Foie -- Maladies -- Périodiques; 616.362
• DOI: 10.1111/hepr.12092
• Languages: English
• ISSNs: 1386-6346

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="hepr12092-sec-0001" sec-type="section"> <title>Aim</title> <p>Several studies using experimental non‐alcoholic fatty liver disease (NAFLD) models have shown that ezetimibe, an inhibitor of cholesterol absorption mainly in the intestine, not only protects against diet‐induced hyperlipidemia, but also attenuates liver steatosis. The aim of this study was to clarify whether ezetimibe inhibits the development of NAFLD and to elaborate the mechanism of ezetimibe to inhibit the development of NAFLD using Fatty Liver Shionogi (FLS) mice, a spontaneous model of NAFLD/non‐alcoholic steatohepatitis.</p> </sec> <sec id="hepr12092-sec-0002" sec-type="section"> <title>Methods</title> <p>Male FLS mice at 20 weeks of age were divided into two groups (<italic>n</italic> = 7 in each group). Mice fed a normal laboratory chow, CRF‐1 or CRF‐1 containing 0.005% w/w ezetimibe (7 mg/kg per day) for 4 weeks. After 4‐week treatment with ezetimibe, the livers of each group of mice were subjected to histological as well as molecular evaluation.</p> </sec> <sec id="hepr12092-sec-0003" sec-type="section"> <title>Results</title> <p>Ezetimibe administration for 4 weeks was associated with improvement of steatosis and fibrosis of the liver in normal diet‐fed FLS mice. Ezetimibe reduced hepatic reactive oxygen species generation and prevented ubiquitination and protein degradation of microsomal triglyceride transfer protein (MTP), a key molecule for very low‐density lipoprotein assembly and export, via downregulation of the protein expression of Skp2 and CDC20.</p> </sec> <sec id="hepr12092-sec-0004" sec-type="section"> <title>Conclusion</title> <p>Ezetimibe not only reduced lipid synthesis in the liver, but also promoted lipid discharge from the liver by preventing post‐translational degradation of MTP via a reduction of hepatic reactive oxygen species generation, leading to inhibition of the development of NAFLD.</p> </sec> </abstract>